NCT03789240View on ClinicalTrials.gov

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 22, 2019

Primary Completion Date

September 24, 2025

Study Completion Date

January 1, 2027

Conditions
Follicular LymphomaNon-Hodgkin's LymphomaNHL
Interventions
BIOLOGICAL

Rituximab

Rituximab is administered at a dose of 375 mg/m2 via IV weekly for the first 4 weeks on Days 1, 8, 15, and 22 during cycle 1. With subsequent cycles (cycles 2-6), rituximab will be dosed only once on Day 1 of the cycle.

DRUG

Copanlisib

Copanlisib is administered at a fixed dose of 60 mg via IV weekly for the first 3 weeks on Days 1, 8, and 15 followed by a 1-week break (no infusion on Day 22)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03789240 - Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | Biotech Hunter | Biotech Hunter